Prevalence of and factors associated with uncontrolled hypertension among patients with early chronic kidney disease attending tertiary hospitals in Dodoma, Tanzania: a cross-sectional study Authors: Denis D Katatwire, Alfred Meremo Published: 2023 ABSTRACT ObjectiveTo determine the prevalence of uncontrolled hypertension and its associated factors among patients with early chronic kidney disease (CKD) attending medical outpatient clinics at tertiary hospitals in Dodoma, Tanzania.DesignCross-sectional study.SettingTwo tertiary hospitals in Dodoma, Tanzania.ParticipantsThe participants in this study were adult patients (≥18 years) with early CKD stages (1, 2 and 3) who were attending nephrology and medical outpatient clinics from November 2020 to March 2021. Patients who had been attending the clinic for at least 3 months, had baseline clinical data on their files, had estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and who provided written informed consent were eligible. A total of 352 patients were enrolled, of whom 182 were men and 170 were women.Outcome measureThe dependent variable was uncontrolled hypertension among patients with early CKD, based on blood pressure measurements.ResultsThe prevalence of hypertension was 58.5% (206 of 352) and the prevalence of uncontrolled hypertension was 58.3% (120 of 206). Among patients with uncontrolled hypertension, 88.3% (106 of 120) had CKD stage 3, 80.2% (96 of 120) reported non-adherence to antihypertensives, 76.7% (92 of 120) were overweight or obese, 72.5% (87 of 120) reported current alcohol use and 26.7% (32 of 120) had diabetes mellitus. Factors that contributed to higher odds of uncontrolled hypertension were: age ≥50 years (OR=5.17, 95 % CI 2.37 to 13.33, p=0.001), alcohol use (OR=11.21, 95% CI 3.83 to 32.84, p=0.001), non-adherence to antihypertensives (OR=10.19, 95% CI 4.22 to 24.61, p=0.001), overweight/obesity (OR=6.28, 95% CI 2.54 to 15.53, p=0.001) and CKD stage 3 (OR=3.52, 95% CI 1.32 to 9.42, p=0.012).ConclusionUncontrolled hypertension was highly prevalent among patients with early CKD in this setting and was associated with age, current alcohol use, non-adherence to antihypertensives, overweight/obesity and declining eGFR. STRENGTHS AND LIMITATIONS OF THIS STUDY This study investigated the prevalence of, and factors associated with, uncontrolled hypertension in a unique population of patients with early chronic kidney disease in Tanzania, a lower middle-income country. This study investigated the prevalence of, and factors associated with, uncontrolled hypertension in a unique population of patients with early chronic kidney disease in Tanzania, a lower middle-income country. We included many different factors associated with uncontrolled hypertension, including previously little studied comorbidities such as proteinuria and anaemia. We included many different factors associated with uncontrolled hypertension, including previously little studied comorbidities such as proteinuria and anaemia. The study is limited by its cross-sectional and observational design. The study is limited by its cross-sectional and observational design. This study was conducted in two hospitals in Dodoma, restricting its generalisability. This study was conducted in two hospitals in Dodoma, restricting its generalisability. Introduction Hypertension is a disease of major public health importance as it remarkably elevates the risk of cardiovascular disease (CVD) and chronic kidney disease (CKD) progression and is a significant cause of deaths worldwide especially in developing countries.1 2 The highest burden of hypertension is in low/middle-income countries (LMICs) where uncontrolled hypertension is highly prevalent with increased complications such as end-stage renal disease (ESRD) and CVD, and increased related morbidity and mortality.3–5 CKD is defined as decreased kidney function identified by glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2, or markers of kidney damage, or both, of at least 3 months’ duration, regardless of the underlying cause.6 7 CKD increases the burden of non-communicable diseases, and it is estimated that the worldwide prevalence of CKD ranges between 10% and 15% depending on the ethnicity, accessibility to health services and treatment of chronic conditions that increase the risk of CKD such as hypertension and diabetes mellitus.8 9 The leading causes of CKD worldwide are diabetes mellitus and hypertension. Unfortunately, in sub-Saharan Africa (SSA), hypertension is the leading cause of CKD.10 11 Uncontrolled hypertension causes and affects CKD thus leading to disease progression as well as increased CVD risks in patients with CKD.12 13 Uncontrolled hypertension is highly prevalent in Africans where it presents in young age and is associated with complications such as CKD, which eventually culminate in ESRD or death.14–16 Patients with CKD have hypertension, and the prevalence of uncontrolled hypertension increases with declining estimated GFR (eGFR).16 17 The African region reported the highest prevalence of hypertension (46%) compared with other regions.18 The prevalence of uncontrolled hypertension among patients with comorbidities in SSA has been reported to be 78.6%, and it was 79.8% in a study conducted in China among patients with CKD.19 20 The prevalence of CKD in Tanzania is estimated to range between 25.7% and 45%, with the leading cause of CKD being hypertension.21–24 The burden of both hypertension and uncontrolled hypertension is expected to increase significantly in Tanzania and in other developing countries due to increasing urbanisation and ongoing epidemiological transition.22 24 25 Poor adherence to antihypertensives, older age, male sex, inadequate diet, lack of exercise, and comorbidities like CKD, diabetes mellitus, and obesity/overweight have been identified as factors associated with increased odds of uncontrolled hypertension.26–28 The prevalence of uncontrolled hypertension increases with declining eGFR. Most of the studies that have been conducted on advanced stages of CKD and studies among patients with early CKD are few. Given this scenario, the aim of this study was to determine the prevalence of uncontrolled hypertension and its associated factors among patients with early CKD attending tertiary hospitals in Dodoma, Tanzania. Methods Study design, population and settings This was a cross-sectional study of adult patients ≥18 years with early CKD stages (1, 2 and 3), who were attending nephrology and medical outpatient clinics at Benjamin Mkapa Hospital and Dodoma Regional Referral Hospital, which are tertiary hospitals in Dodoma, Tanzania, from November 2020 to March 2021. Patients were referred to these hospitals by clinicians/general practitioners from other clinics and district hospitals for specialist care. Early CKD was defined as patients with CKD stages 1, 2 and 3 as per their eGFR calculations according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.7 29 Inclusion criteria included: patients ≥18 years of age, attending the clinic for at least 3 months, eGFR ≥30 mL/min/1.73 m2 and who gave written informed consent. Data collection and laboratory procedures Enrolment occurred from November 2020 to March 2021. The sample size was obtained using Kish and Leslie’s sample size calculation based on a study conducted in China with 79.8% of uncontrolled hypertension including an assumption of 95% level of confidence and 5% of errors.20 Therefore, the minimum required sample size of this study was 298 patients who had early CKD. Consecutive sampling technique was used whereby every patient who met the inclusion criteria during the study period was enrolled into the study until the last participant.30 CKD categories were based on their eGFR as per CKD-EPI formula based on data from ongoing continuous medical outpatient department (OPD) clinic records. After the patients consented to participate in the study, face-to-face interviews were conducted to collect data on age, gender, history of smoking, alcohol use, comorbidities such as diabetes mellitus, hypertension and adherence to antihypertensives using the Morisky Medication Adherence Scale. Blood pressure was measured; systolic (SBP) and diastolic blood pressure (DBP) were measured three times. The average of the second and third measurements was used.31 Weight, height, waist circumference and body mass index (BMI) were calculated using the National Health Services-UK BMI calculator.32 Blood for serum creatinine measurements was collected in the laboratory and analysed using the isotope dilution mass spectrometry traceable assay and the eGFR was calculated using the CKD-EPI equation without using the African American correction factor.33 Urinary protein–creatinine ratio (uPCR) was calculated by dividing the amount of protein (g/dL) by the creatinine level (g/dL) in a spot urine test.34 Other laboratory investigations such as haemoglobin A1c (HbA1c), full blood picture, fasting blood sugar and lipid profile were performed and analysed by Cobas 6000 analyser (Roche Diagnostics, USA). Outcome variable The main outcome variable in this study was uncontrolled hypertension among patients with early CKD. Patients with uncontrolled hypertension were those with SBP ≥140 mm Hg, DBP ≥90 mm and were on treatment with antihypertensive medications or were not on treatment.7 35 Adherence to antihypertensives was defined according to the Morisky Medication Adherence Scale whereby a Morisky score of ≤2 represented non-adherence and a Morisky score >2 represented good adherence.36 Independent variables The independent variables consisted of individual characteristics, that is, age, gender, marital status, education level, occupation, residency, history of smoking, alcohol use, comorbidities such as diabetes mellitus, antihypertensives, adherence to antihypertensives, CKD stages, BMI, uPCR, eGFR, HbA1c, fasting blood glucose, haemoglobin and lipid profile. BMI categories were according to the WHO, namely: underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25.0–29.0 kg/m2) and obese (≥30.0 kg/m2).37 Dyslipidaemia (impaired lipid profile) was defined according to the best practices whereby total cholesterol=≥5 mmol/L (190 mg/dL), triglycerides=≥2 mmol/L (175 mg/dL), low-density lipoprotein cholesterol=≥3 mmol/L (115 mg/dL) and high-density lipoprotein cholesterol=≤1 mmol/L (40 mg/dL).38 39 Diabetes mellitus was defined as fasting blood glucose of ≥7 mmol/L or HbA1c ≥6.5.40 41 Data management and analysis The collected data were entered into an Excel spreadsheet and analysed by IBM SPSS statistics (V.26) predictive analytics software. Any errors were cross-checked and data cleaning was done. Descriptive statistics were used to summarise variables as proportions and frequency tables for categorical variables. Depending on whether variables were normally distributed, medians with IQRs were used to summarise continuous data, and differences between those with normotensive, controlled and uncontrolled hypertension were compared using the χ2 test for normally distributed variables and Mann-Whitney U test for non-normally distributed variables. Logistic regression was performed to assess the relationship between uncontrolled hypertension and associated variables using the crude and adjusted ORs with their 95% CIs for significant differences between the groups. Variables with a p value less than 0.2 on univariate logistic regression models were then fitted into the multivariate logistic regression models; variables with a p value of less than 0.05 were considered to have significant strength of association. Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details. Results A total of 658 patients attended nephrology, hypertension, diabetic and medical OPD clinics during the 4 months of enrolment. A total of 306 patients were excluded from the study including 234 patients who did not have CKD, 69 patients who had advanced CKD (CKD stages 4 and 5) and 3 patients who did not provide written informed consent. A total of 206 (58.5%) enrolled patients were diagnosed with hypertension, of whom 120 (58.3%) had uncontrolled hypertension (figure 1). Enrolment flow chart for our study participants. BMH, Benjamin Mkapa Hospital; CKD, chronic kidney disease; DRRH, Dodoma Regional Referral Hospital; MOPD, medical outpatient department. Baseline and demographic characteristics of the study patients A total of 352 patients with median age of 54 (47–59) years met the criteria to be included in this study, where 182 (51.7%) were males, 252 (71.6%) were married, 205 (58.2%) were living in urban areas and 258 (73.3) had at least secondary-level education. The prevalence of hypertension was 58.5% (206 of 352) and the prevalence of uncontrolled hypertension was 58.3% (120 of 206). For those with uncontrolled hypertension, the median age was 55 (50–60) years, the median SBP was 146 (142–150) mm Hg, the median DBP was 86 (82–90) mm Hg, the median BMI was 26.1 (24.0–27.5) kg/m2, the median eGFR was 48 (43–55) mL/min/1.73 m2 and the median uPCR was 0.025 (IQR 0.025–0.130) g/mmol (table 1). Table 1Sociodemographic and clinical data of the patients with early CKD by their hypertensive status (n=352)VariablesUncontrolled hypertension (n=120)Controlled hypertension (n=86)Normotensive (n=146)P valueMedian (IQR) or proportion (%)Median (IQR) or proportion (%)Median (IQR) or proportion (%)Age (years)55 (50–60)48 (45–56)54 (48–59) 0.001 Sex Male61 (50.8)48 (55.8)73 (50)0.631 Female59 (49.2)38 (44.2)73 (50)Marital status Married87 (72.5)57 (66.3)111 (76.0)0.399 Single33 (27.5)29 (33.7)35 (24.0)Level of education Primary or less38 (31.7)19 (22.1)50 (34.2)0.221 Secondary and above82 (68.3)67 (77.9)96 (65.8)Residence Rural58 (48.3)32 (22.1)58 (39.7)0.232 Urban62 (51.7)54 (77.9)88 (60.3)Occupation Employed49 (40.8)30 (34.9)41 (28.1)0.712 Self-employed71 (59.2)56 (65.1)105 (71.9)NHIF status Insured47 (39.2)31 (36.0)70 (47.9)0.093 Not insured73 (60.8)55 (64.0)76 (52.1)SBP (mm Hg)146 (142–150)125 (120–128)122 (120–128) 0.001 DBP (mm Hg)86 (82–90)80 (76–84)78 (76–82) 0.001 BMI (kg/m2)26.1 (24.0–27.5)24.4 (23.4–26.0)25.5 (24.4–30.8) 0.001 Waist circumference (cm)97 (90–104)90 (84.5–103.0)91.5 (81.0–104.0) 0.003 Hb (g/dL)12.4 (10.9–13.2)12.6 (11.4–13.2)3 (11.0–13.2)0.289FBG (mmol/L)5.3 (4.9–6.2)5.1 (4.9–5.7)5.0 (4.8–5.5) 0.001 HbA1c (%)6.2 (5.8–6.7)5.6 (5.0–6.0)5.8 (5.7–6.2) 0.020 Creatinine (µmol/L)130.9 (123.0–138.9)124.2 (120.5–137.7)119 (116.4–132.2) 0.025 eGFR (mL/min/1.73 m2)48 (43–55)53 (45–62)55 (53–61) 0.001 BUN (mmol/L)8.0 (7.2–8.9)7.4 (6.9–8.3)6.7 (6.4–7.4) 0.013 uPCR (g/g)0.025 (0.025–0.130)0.025 (0.02–0.027)0.025 (0.025–0.120) 0.001 Total cholesterol (mmol/L)5.4 (4.5–6.0)4.8 (4.1–5.9)4.0 (4.1–4.7)0.164Triglycerides (mmol/L)4.6 (1.5–5.4)1.6 (1.5–5.0)3 (1.5–4.8)0.251HDL-C (mmol/L)1.2 (0.8–1.4)1.3 (0.9–1.7)1.3 (0.8–1.5) 0.008 LDL-C (mmol/L)3.8 (3.1–4.4)3.3 (3.0–4.0)3.5 (3.1–4.2)0.200BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; Hb, haemoglobin; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NHIF, National Health Insurance Fund; SBP, systolic blood pressure; uPCR, urinary protein–creatinine ratio. Sociodemographic and clinical data of the patients with early CKD by their hypertensive status (n=352) BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; Hb, haemoglobin; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NHIF, National Health Insurance Fund; SBP, systolic blood pressure; uPCR, urinary protein–creatinine ratio. Clinical profile of the study participants Of the 120 patients with uncontrolled hypertension, 88.3% (106 of 120) of patients had CKD stage 3, 80.2% (96 of 120) of patients reported non-adherence to antihypertensives, 76.7% (92 of 120) of patients were overweight/obese and 72.5% (87 of 120) of patients reported current alcohol use (table 2). Table 2Clinical profile of the patients with early CKD by their hypertensive status (n=206)VariablesUncontrolled hypertension(n=120)Proportion (%)Controlled hypertension(n=86)Proportion (%)P valueAge (years) <5026 (21.7)47 (54.7) 0.001 ≥5094 (78.3)39 (45.3)Current alcohol use No33 (27.5)56 (65.1) 0.001 Yes87 (72.5)30 (34.9)Current smoking No68 (56.6)61 (70.9) 0.028 Yes52 (43.3)24 (29.1)Diabetes mellitus status No88 (73.3)73 (84.9) 0.048 Yes32 (26.7)13 (15.1)Adherence to antihypertensives (Morisky score) ≤224 (20.0)51 (59.3) 0.001 >296 (80.2)35 (40.7)Overweight or obesity No28 (23.3)45 (52.3) 0.001 Yes92 (76.7)41 (47.7)Anaemia status No70 (58.3)56 (65.1)0.326 Yes50 (41.7)30 (34.9)CKD stage 214 (11.7)29 (33.7) 0.001 3106 (88.3)57 (66.3)Lipid profile Normal48 (40.0)48 (55.8) 0.025 Impaired72 (60.0)38 (44.2)uPCR (g/g) <0.0376 (63.3)75 (87.2) 0.003 ≥0.0344 (36.7)11 (12.8)Antihypertensive medication Thiazide diuretics82 (68.3)63 (72.4)0.146 ACEIs/ARBs86 (71.6)58 (66.7)0.245 CCBs98 (81.7)74 (85.1)0.081 Beta-blockers31 (25.8)28 (32.2)0.517 Others23 (19.2)19 (21.8)0.423ACEIs, ACE inhibitors; ARBs, aldosterone receptor blockers; CCBs, calcium channel blockers; CKD, chronic kidney disease; uPCR, urinary protein–creatinine ratio. Clinical profile of the patients with early CKD by their hypertensive status (n=206) ACEIs, ACE inhibitors; ARBs, aldosterone receptor blockers; CCBs, calcium channel blockers; CKD, chronic kidney disease; uPCR, urinary protein–creatinine ratio. Factors associated with uncontrolled hypertension We divided the patients into two subgroups: uncontrolled hypertension ≥140/90 mm Hg vs controlled hypertension <140/90 mm Hg. A total of 15 potential variables were identified after performing univariate logistic regression analyses. Backward elimination reduced this to 10 parameters. The factors independently associated with uncontrolled hypertension on multivariate logistic regression analysis included: age ≥50 years (OR=5.17, 95% CI 2.37 to 13.33, p=0.001), alcohol use (OR=11.21, 95% CI 3.83 to 32.84, p=0.001), overweight and obesity (OR=6.28, 95% CI 2.54 to 15.53, p=0.001), non-adherence to antihypertensives (Morisky score >2) (OR=10.19, 95% CI 4.22 to 24.61, p=0.001) and CKD stage 3 (OR=3.52, 95% CI 1.32 to 9.42, p=0.012) (table 3). Table 3Factors associated with uncontrolled hypertension (n=120)VariablesNo of patientsUnivariateMultivariateCOR (95% CI)P valueAOR (95% CI)P valueAge <5026Ref 0.001 ≥50944.36 (2.37 to 8.01)0.0015.62 (2.37 to 13.33)Residence Urban58RefRef0.379 Rural621.50 (0.86 to 2.64)0.1561.43 (0.64 to 3.18)Alcohol use No33RefRef 0.001 Yes877.85 (3.70 to 16.64)0.00111.21 (3.83 to 32.84)Smoking No68RefRef0.179 Yes521.94 (1.07 to 3.52)0.0281.76 (0.77 to 4.03)Diabetes mellitus status No880.613 Yes322.04 (0.99 to 4.18)0.0501.32 (0.45 to 3.81)Overweight or obesity Normal28RefRef 0.001 Increased923.61 (1.98 to 6.56)0.0016.28 (2.54 to 15.53)Adherence to antihypertensives ≤224RefRef 0.001 >2965.83 (3.13 to 10.84)0.00110.19 (4.22 to 24.61)CKD stage 214RefRef 0.012 31063.85 (1.89 to 7.87)0.0013.52 (1.32 to 9.42)Proteinuria No76RefRef0.121 Yes442.74 (1.40 to 5.35)0.0032.24 (0.81 to 6.24)Lipid profile Normal48RefRef0.432 Impaired721.90 (1.08 to 3.32)0.0261.39 (0.61 to 3.12)AOR, adjusted OR; CKD, chronic kidney disease; COR, crude OR. Factors associated with uncontrolled hypertension (n=120) AOR, adjusted OR; CKD, chronic kidney disease; COR, crude OR. Discussion This study evaluated the prevalence of uncontrolled hypertension and its associated factors among patients with early CKD attending medical outpatient clinics in tertiary hospitals in Dodoma, Tanzania. The prevalence of uncontrolled hypertension among patients with early CKD in this study was 58.3%. This is lower than the findings from other previous studies conducted in Tanzania, which reported 66% prevalence in Dar es Salaam and 84.5% in Mwanza.42 43 Our study findings are also lower when compared with systematic reviews and meta-analyses of uncontrolled hypertension among patients with comorbidities in SSA which reported a prevalence ranging between 69.9% and 78.6% among patients with comorbidities and 79.8% among patients with CKD in China.19 20 25 These differences could be accounted by variations in the studied populations. The other previous studies were conducted among patients majority of whom were diagnosed with comorbidities including those with diabetes mellitus and those who had advanced CKD. Unhealthy behaviours including overweight/obesity, excessive alcohol intake and smoking are associated with uncontrolled hypertension.28 44 45 Uncontrolled deposition of adipose tissues leads to elevated blood pressure accounting for 65–75% of all primary hypertension. Hypertension is a known significant cause of CKD and CKD progression.46 47 In this study, 76.7% of patients with uncontrolled hypertension were found to have overweight/obesity, and people with overweight/obesity had sixfold increased odds of uncontrolled hypertension. These findings are similar to previous studies conducted in Tanzania.43 48 49 Tanzania and other third world countries are undergoing epidemiological transition associated with urbanisation and sedentary lifestyle with increasing overweight/obesity, dyslipidaemia, hypertension, diabetes, CVDs and CKD.27 30 46 In this study, the prevalence of dyslipidaemia among patients with uncontrolled hypertension was 60.0%, similar to the findings from previous studies where the prevalence increased with uncontrolled hypertension and across the CKD stages from 1 to 5.50 51 The prevalence of dyslipidaemia among patients with uncontrolled hypertension and CKD is usually high.52 53 Dyslipidaemia is associated with rapid CKD progression, and increased morbidity and mortality from CVD.54 Most (72.5%) of our study participants who had uncontrolled hypertension reported using alcohol, and alcohol use was found to result in 11 times increased risk of uncontrolled hypertension. Similar findings have been reported from previous studies.28 55 56 About one-third (36.9%) of the patients with uncontrolled hypertension had a history of current smoking, similar to the findings from previous studies.57 58 Unlike in other studies, in the current study, smoking was not associated with uncontrolled hypertension possibly due to few numbers of patients who did report to have been smoking. Non-adherence to antihypertensives has been reported to be an important reason for high rates of uncontrolled hypertension in SSA.27 28 36 In this study, 80.2% of the patients who had uncontrolled hypertension were not adhering to their antihypertensives as they had a Morisky score >2, and non-adherence to antihypertensives led to a 10-fold increased risk of uncontrolled hypertension. Similar findings have been reported from previous studies.36 59 60 Uncontrolled hypertension tends to develop and/or get worse as the CKD progresses.61 Patients with advanced CKD have increased odds of uncontrolled hypertension.7 26 In this study, majority of the participants (81.8%) had CKD stage 3, and those with CKD stage 3 had 3.5-fold increased odds of uncontrolled hypertension. These findings are similar to the findings from other studies that did demonstrate declining eGFR as a risk factor for uncontrolled hypertension.35 62 More than one-third of the patients (36.7%) with uncontrolled hypertension presented themselves with proteinuria. This finding is similar to the findings from previous studies that did demonstrate kidney damage to be common among patients with uncontrolled hypertension.63 64 However, unlike other studies, in the current study, proteinuria was not associated with uncontrolled hypertension, possibly due to few numbers of patients who were found with proteinuria. This could be due to the fact that this study was done among patients with early CKD and majority (81.7%) of the patients were on calcium channel blockers and 71.6% of the patients were also on ACE inhibitors (ACEIs)/aldosterone receptor blockers (ARBs). Previous studies did demonstrate the role of ACEIs/ARBs and calcium channel blockers in decreasing proteinuria and CKD progression.65 66 Age has been associated with increased risk of CKD and CKD progression where studies have demonstrated that younger age of CKD onset and increasing age are associated with a more rapid progression of CKD.14 67 The median age of the participants who had uncontrolled hypertension was 55 (50–60) years; age ≥50 years had five times increased odds of uncontrolled hypertension among patients with early CKD. These findings have been observed in previous studies conducted in LMICs where the onset of CKD in SSA is significantly higher in younger people compared with the developed countries where the onset of CKD is more common among the elderly.27 35 62 Studies have also demonstrated that uncontrolled hypertension is associated with increasing age in CKD.14 35 68 The limitations of this study include its cross-sectional, observational design and the restricted setting—as the study was conducted in two tertiary hospitals in Dodoma, the findings are not necessarily generalisable to other parts of Tanzania. Despite these limitations, this study provides data on the high prevalence of CVD risk factors in those with early CKD from a treatment and healthcare resource perspective. Conclusion Uncontrolled hypertension was highly prevalent among patients with early CKD in this setting and was associated with age, current alcohol use, overweight/obesity, non-adherence to antihypertensives and declining eGFR. Clinicians should strive to improve adherence to antihypertensives and lifestyle modifications among patients who are diagnosed with hypertension. Supplementary Material Reviewer comments Author's manuscript